Literature DB >> 28323995

Renin Phenotypes Characterize Vascular Disease, Autonomous Aldosteronism, and Mineralocorticoid Receptor Activity.

Gregory L Hundemer1, Rene Baudrand2, Jenifer M Brown3, Gary Curhan1, Gordon H Williams3, Anand Vaidya3.   

Abstract

Context: Mild cases of autonomous aldosterone secretion may go unrecognized using current diagnostic criteria for primary aldosteronism (PA). Objective: To investigate whether the inability to stimulate renin serves as a biomarker for unrecognized autonomous aldosterone secretion and mineralocorticoid receptor (MR) activation. Participants: Six hundred sixty-three normotensive and mildly hypertensive participants, who were confirmed to not have PA using current guideline criteria and were on no antihypertensive medications. Design: Participants had their maximally stimulated plasma renin activity (PRA) measured while standing upright after sodium restriction. Tertiles of maximally stimulated PRA were hypothesized to reflect the degree of MR activation: lowest PRA tertile = "Inappropriate/Excess MR Activity;" middle PRA tertile = "Intermediate MR Activity;"; and highest PRA tertile = "Physiologic MR Activity." All participants underwent detailed biochemical and vascular characterizations under conditions of liberalized sodium intake, and associations with stimulated PRA phenotypes were performed.
Results: Participants with lower stimulated PRA had greater autonomous aldosterone secretion [higher aldosterone-to-renin ratio (P = 0.002), higher urine aldosterone excretion rate (P = 0.003), higher systolic blood pressure (P = 0.004), and lower renal plasma flow (P = 0.04)] and a nonsignificant trend toward lower serum potassium and higher urine potassium excretion, which became significant after stratification by hypertension status. Conclusions: In participants without clinical PA, the inability to stimulate renin was associated with greater autonomous aldosterone secretion, impaired vascular function, and suggestive trends in potassium handling that indicate an extensive spectrum of unrecognized MR activation.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28323995      PMCID: PMC5470762          DOI: 10.1210/jc.2016-3867

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors.

Authors:  Yiling Fu; John E Hall; Deyin Lu; Lin Lin; R Davis Manning; Liang Cheng; Celso E Gomez-Sanchez; Luis A Juncos; Ruisheng Liu
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

2.  Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study.

Authors:  Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams
Journal:  J Clin Endocrinol Metab       Date:  2012-04-26       Impact factor: 5.958

Review 3.  Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited.

Authors:  Bernard C Rossier; Michael E Baker; Romain A Studer
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

4.  The association of plasma resistin with dietary sodium manipulation, the renin-angiotensin-aldosterone system, and 25-hydroxyvitamin D3 in human hypertension.

Authors:  Anand Vaidya; Luminita Pojoga; Patricia C Underwood; John P Forman; Paul N Hopkins; Gordon H Williams; Jonathan S Williams
Journal:  Clin Endocrinol (Oxf)       Date:  2011-03       Impact factor: 3.478

5.  Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China.

Authors:  Xiaojing Sang; Yiran Jiang; Weiqing Wang; Li Yan; Jiasheng Zhao; Yongde Peng; Wei Gu; Gang Chen; Wei Liu; Guang Ning
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

6.  Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry.

Authors:  M Reincke; C Meisinger; R Holle; M Quinkler; S Hahner; F Beuschlein; M Bidlingmaier; J Seissler; S Endres
Journal:  Horm Metab Res       Date:  2010-01-29       Impact factor: 2.936

7.  Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors.

Authors:  Aurelie Nguyen Dinh Cat; Ana M Briones; Glaucia E Callera; Alvaro Yogi; Ying He; Augusto C Montezano; Rhian M Touyz
Journal:  Hypertension       Date:  2011-07-25       Impact factor: 10.190

8.  Aldosterone production and insulin resistance in healthy adults.

Authors:  Rajesh Garg; Shelley Hurwitz; Gordon H Williams; Paul N Hopkins; Gail K Adler
Journal:  J Clin Endocrinol Metab       Date:  2010-02-03       Impact factor: 5.958

9.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

10.  Abnormal aldosterone physiology and cardiometabolic risk factors.

Authors:  Anand Vaidya; Patricia C Underwood; Paul N Hopkins; Xavier Jeunemaitre; Claudio Ferri; Gordon H Williams; Gail K Adler
Journal:  Hypertension       Date:  2013-02-11       Impact factor: 10.190

View more
  11 in total

Review 1.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 2.  MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism.

Authors:  Gregory L Hundemer; Anand Vaidya
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

3.  Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study.

Authors:  María Fernández-Argüeso; Eider Pascual-Corrales; Nuria Bengoa Rojano; Ana García Cano; Lucía Jiménez Mendiguchía; Marta Araujo-Castro
Journal:  Endocrine       Date:  2021-04-02       Impact factor: 3.633

Review 4.  Primary aldosteronism - a multidimensional syndrome.

Authors:  Adina F Turcu; Jun Yang; Anand Vaidya
Journal:  Nat Rev Endocrinol       Date:  2022-08-31       Impact factor: 47.564

Review 5.  Primary Aldosteronism Diagnosis and Management: A Clinical Approach.

Authors:  Gregory L Hundemer; Anand Vaidya
Journal:  Endocrinol Metab Clin North Am       Date:  2019-12       Impact factor: 4.741

6.  The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study.

Authors:  Jenifer M Brown; Cassianne Robinson-Cohen; Miguel Angel Luque-Fernandez; Matthew A Allison; Rene Baudrand; Joachim H Ix; Bryan Kestenbaum; Ian H de Boer; Anand Vaidya
Journal:  Ann Intern Med       Date:  2017-10-10       Impact factor: 25.391

7.  Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  Hypertension       Date:  2018-09       Impact factor: 9.897

8.  Association of Serum Aldosterone and Plasma Renin Activity With Ambulatory Blood Pressure in African Americans: The Jackson Heart Study.

Authors:  Joshua J Joseph; Neal K Pohlman; Songzhu Zhao; David Kline; Guy Brock; Justin B Echouffo-Tcheugui; Mario Sims; Valery S Effoe; Wen-Chih Wu; Rita R Kalyani; Gary S Wand; Bjorn Kluwe; Willa A Hsueh; Marwah Abdalla; Daichi Shimbo; Sherita H Golden
Journal:  Circulation       Date:  2021-02-19       Impact factor: 39.918

Review 9.  The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Int J Mol Sci       Date:  2018-02-11       Impact factor: 5.923

Review 10.  Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.

Authors:  Anand Vaidya; Robert M Carey
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.